spironolactone has been researched along with Uremia in 28 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Blood pressure, heart rate, concentrations of aldosterone, urea, creatinine, electrolytes, and protein, index of hypertrophy of visceral organs, and 24-h diuresis were evaluated." | 7.74 | Effect of spironolactone on hypertrophy of left ventricular myocardium in wistar rats with experimental uremia. ( Beresneva, ON; Esaian, AM; Karabayeva, AZh; Kayukov, IG; Kotenko, LV; Parastaeva, MM; Sevastyanova, IE, 2008) |
| "The aim of this study was to specify the mechanism of hepatic encephalopathy which may occur in some cirrhotics treated by Spironolactone." | 7.65 | [Hyperammonemia and hepatic encephalopathy in cirrhotics receiving spironolactone (author's transl)]. ( Imler, M; Schlienger, JL, 1977) |
| "Aldosterone was in the past considered only as a prohypertensinogenic agent." | 6.46 | Aldosterone in uremia - beyond blood pressure. ( Koleganova, N; Ritz, E, 2010) |
| "Prompt recognition of the arrhythmia and immediate restoration of the cardiac rate and rhythm by pacemaker support followed by intensive regimen to lower the serum potassium prevented a potentially fatal outcome." | 5.26 | Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia. ( Patel, A; Thomsen, J; Yap, V, 1976) |
| "Five patients (three in the placebo and two in the spironolactone group) abandoned the treatment prior to ascites recurrence or the end of the study due to complications or lack of compliance." | 5.08 | Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. ( Adler, M; Arroyo, V; Elewaut, A; Fernández-Esparrach, G; Geuvel, A; Ginès, P; Guevara, M; Jiménez, W; Lebrec, D; Pardo, A; Planas, R; Sort, P, 1997) |
| " Blood pressure, heart rate, concentrations of aldosterone, urea, creatinine, electrolytes, and protein, index of hypertrophy of visceral organs, and 24-h diuresis were evaluated." | 3.74 | Effect of spironolactone on hypertrophy of left ventricular myocardium in wistar rats with experimental uremia. ( Beresneva, ON; Esaian, AM; Karabayeva, AZh; Kayukov, IG; Kotenko, LV; Parastaeva, MM; Sevastyanova, IE, 2008) |
| "Twenty-seven patients with nonazotemic liver cirrhosis and ascites were initially treated with spironolactone, 200 mg/day." | 3.70 | Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients. ( Banić, M; Kujundzić, M; Ljubicić, N; Vrkljan, M, 1998) |
| " Plasma samples from non-digitalized patients of the following categories were assayed: uncomplicated essential hypertension treated with spironolactone, uremia, and acute myocardial infarction (AMI)." | 3.66 | Precision of digoxin radioimmunoassays and matrix effects: four kits compared. ( Bergdähl, B; Molin, L, 1981) |
| "The aim of this study was to specify the mechanism of hepatic encephalopathy which may occur in some cirrhotics treated by Spironolactone." | 3.65 | [Hyperammonemia and hepatic encephalopathy in cirrhotics receiving spironolactone (author's transl)]. ( Imler, M; Schlienger, JL, 1977) |
| "In 8 out of 20 patients with chronic liver disease ascites was controlled with metolazone, 10 required additional amiloride or spironolactone to achieve control, and 2 were resistant to all diuretic therapy." | 3.65 | Use of metolazone in the treatment of ascites due to liver disease. ( Hillenbrand, P; Sherlock, S, 1971) |
| "Aldosterone was in the past considered only as a prohypertensinogenic agent." | 2.46 | Aldosterone in uremia - beyond blood pressure. ( Koleganova, N; Ritz, E, 2010) |
| "Spironolactone has been noted to attenuate cardiac fibrosis." | 1.35 | Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. ( Bagrov, AY; Cooper, CJ; El-Okdi, N; Elkareh, J; Fedorova, OV; Gohara, S; Gupta, S; Haller, S; Malhotra, D; Periyasamy, SM; Shapiro, JI; Shidyak, A; Taleb, M; Tian, J; Xie, Z, 2009) |
| "Prompt recognition of the arrhythmia and immediate restoration of the cardiac rate and rhythm by pacemaker support followed by intensive regimen to lower the serum potassium prevented a potentially fatal outcome." | 1.26 | Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia. ( Patel, A; Thomsen, J; Yap, V, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (64.29) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tatsumoto, N | 1 |
| Yamada, S | 1 |
| Tokumoto, M | 1 |
| Eriguchi, M | 1 |
| Noguchi, H | 1 |
| Torisu, K | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Michea, L | 1 |
| Villagrán, A | 1 |
| Urzúa, A | 1 |
| Kuntsmann, S | 1 |
| Venegas, P | 1 |
| Carrasco, L | 1 |
| Gonzalez, M | 1 |
| Marusic, ET | 1 |
| Karabayeva, AZh | 1 |
| Esaian, AM | 1 |
| Kayukov, IG | 1 |
| Parastaeva, MM | 1 |
| Beresneva, ON | 1 |
| Kotenko, LV | 1 |
| Sevastyanova, IE | 1 |
| Rasmussen, ZZ | 1 |
| Barfod, T | 1 |
| Klit, J | 1 |
| Tian, J | 1 |
| Shidyak, A | 1 |
| Periyasamy, SM | 1 |
| Haller, S | 1 |
| Taleb, M | 1 |
| El-Okdi, N | 1 |
| Elkareh, J | 1 |
| Gupta, S | 1 |
| Gohara, S | 1 |
| Fedorova, OV | 1 |
| Cooper, CJ | 1 |
| Xie, Z | 1 |
| Malhotra, D | 1 |
| Bagrov, AY | 1 |
| Shapiro, JI | 1 |
| Ritz, E | 1 |
| Koleganova, N | 1 |
| SAMBHI, MP | 1 |
| BECK, JC | 1 |
| VENNING, EH | 1 |
| JOHNSTON, LC | 1 |
| GRIEBLE, HG | 1 |
| SCHOENBERGER, JA | 1 |
| FULLER, JB | 1 |
| BERNSTEIN, A | 1 |
| ODZE, M | 1 |
| CREWS, A | 1 |
| SIMON, F | 1 |
| HAYES, CP | 2 |
| ROBINSON, RR | 2 |
| Svensson, M | 1 |
| Gustafsson, F | 1 |
| Galatius, S | 1 |
| Hildebrandt, PR | 1 |
| Atar, D | 1 |
| McLeod, ME | 1 |
| Bergdähl, B | 1 |
| Molin, L | 1 |
| Fernández-Esparrach, G | 1 |
| Guevara, M | 1 |
| Sort, P | 1 |
| Pardo, A | 1 |
| Jiménez, W | 1 |
| Ginès, P | 1 |
| Planas, R | 1 |
| Lebrec, D | 1 |
| Geuvel, A | 1 |
| Elewaut, A | 1 |
| Adler, M | 1 |
| Arroyo, V | 1 |
| Ljubicić, N | 1 |
| Kujundzić, M | 1 |
| Banić, M | 1 |
| Vrkljan, M | 1 |
| Mayan, H | 1 |
| Kantor, R | 1 |
| Farfel, Z | 1 |
| Lawson, DH | 1 |
| Hutcheon, AW | 1 |
| Jick, H | 1 |
| Imler, M | 1 |
| Schlienger, JL | 1 |
| Gifford, RW | 1 |
| Yap, V | 1 |
| Patel, A | 1 |
| Thomsen, J | 1 |
| Kincaid-Smith, P | 1 |
| Fang, P | 1 |
| Laver, MC | 1 |
| Sherlock, S | 2 |
| Senewiratne, B | 1 |
| Scott, A | 1 |
| Walker, JG | 1 |
| Kim, KE | 1 |
| Onesti, G | 1 |
| Swartz, C | 1 |
| Schwarzbach, W | 1 |
| Bunzl, W | 1 |
| Leiter, L | 1 |
| Baglin, A | 1 |
| Safar, M | 1 |
| Milliez, P | 1 |
| Hillenbrand, P | 1 |
| Wilson, DR | 1 |
| Ing, TS | 1 |
| Metcalfe-Gibson, A | 1 |
| Wrong, OM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for spironolactone and Uremia
| Article | Year |
|---|---|
Aldosterone in uremia - beyond blood pressure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Endothelial Cells; Endothelium, Vascular; | 2010 |
Combinations of diuretics in the treatment of edema.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Edema; Ethacrynic Acid; Furosemide; Glu | 1970 |
2 trials available for spironolactone and Uremia
| Article | Year |
|---|---|
Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
Topics: Aldosterone; Ascites; Combined Modality Therapy; Diuretics; Dose-Response Relationship, Drug; Double | 1997 |
A new look at the treatment of severe hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Chlorothiazide; Clinica | 1973 |
24 other studies available for spironolactone and Uremia
| Article | Year |
|---|---|
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Topics: Adenine; Animals; Aorta, Abdominal; Aortic Diseases; Apoptosis; Biomarkers; Disease Models, Animal; | 2015 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
Topics: Analysis of Variance; Animals; Biomarkers; Blotting, Western; Cardiomegaly; Disease Models, Animal; | 2008 |
Effect of spironolactone on hypertrophy of left ventricular myocardium in wistar rats with experimental uremia.
Topics: Aldosterone; Animals; Creatinine; Electrolytes; Hypertrophy, Left Ventricular; Kidney Failure, Chron | 2008 |
[Renal effect of treatment for heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diuretics; Furosemide; Heart Failure; Hu | 2009 |
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Topics: Animals; Bufanolides; Canrenone; Cardiomyopathies; Cardiotonic Agents; Cells, Cultured; Disease Mode | 2009 |
MALIGNANT HYPERTENSION AND ALDOSTERONE SECRETION. INFLUENCE OF REVERSAL AND PROGRESSION OF THE SYNDROME IN TWO CASES.
Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypertension, Malignant; Spironolactone; Urem | 1963 |
TREATMENT OF ARTERIAL HYPERTENSIVE DISEASE WITH DIURETICS. III. CHLORTHALIDONE ALONE AND IN COMBINATION WITH SPIRONOLACTONE.
Topics: Bendroflumethiazide; Cardiomegaly; Chlorides; Chlorthalidone; Coronary Disease; Creatine; Creatinine | 1964 |
ETHACRYNIC ACID: A NEW POTENT DIURETIC.
Topics: Alkalosis; Blood Chemical Analysis; Blood Urea Nitrogen; Body Weight; Digitalis Glycosides; Diuresis | 1965 |
FECAL POTASSIUM EXCRETION IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS.
Topics: Chlorothiazide; Diet; Drug Therapy; Feces; Humans; Kidney; Kidneys, Artificial; Potassium; Prednison | 1965 |
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2003 |
An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure.
Topics: Chlorothiazide; Creatinine; Diet; Feces; Humans; Kidney Failure, Chronic; Kidney Function Tests; Met | 1967 |
Precision of digoxin radioimmunoassays and matrix effects: four kits compared.
Topics: Digoxin; False Positive Reactions; Humans; Hypertension; Myocardial Infarction; Radioimmunoassay; Re | 1981 |
Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.
Topics: Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis, Alcoholi | 1998 |
Trans-tubular potassium gradient in patients with drug-induced hyperkalemia.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Creatinin | 2001 |
Life threatening drug reactions amongst medical in-patients.
Topics: Aged; Arrhythmias, Cardiac; Bethanidine; Digoxin; Drug-Related Side Effects and Adverse Reactions; F | 1979 |
[Hyperammonemia and hepatic encephalopathy in cirrhotics receiving spironolactone (author's transl)].
Topics: Adult; Aged; Ammonia; Hepatic Encephalopathy; Humans; Intestinal Mucosa; Liver Cirrhosis; Male; Midd | 1977 |
A guide to the practical use of diuretics.
Topics: Administration, Oral; Diuretics; Edema; Furosemide; Humans; Hypercalcemia; Hyperglycemia; Hypertensi | 1976 |
Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia.
Topics: Aged; Arrhythmias, Cardiac; Humans; Hyperkalemia; Male; Potassium; Salts; Spironolactone; Uremia | 1976 |
Complications of diuretic therapy in hepatic cirrhosis.
Topics: Chlorothiazide; Diuretics; Ethacrynic Acid; Furosemide; Hepatic Encephalopathy; Humans; Hypokalemia; | 1966 |
Problems in therapy for the hypertensive patient.
Topics: Antihypertensive Agents; Blood Pressure; Carotid Sinus; Diuretics; Electric Stimulation; Ethacrynic | 1973 |
[Urea and spironolactone therapy].
Topics: Adolescent; Adult; Aged; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyper | 1973 |
[Malignant arterial hypertension. Intensive treatment by acute sodium depletion and antihypertensive agents].
Topics: Adult; Antihypertensive Agents; Body Weight; Creatinine; Diet, Sodium-Restricted; Diuretics; Female; | 1972 |
Use of metolazone in the treatment of ascites due to liver disease.
Topics: Adult; Ascites; Chlorides; Chronic Disease; Diuretics; Female; Hepatic Encephalopathy; Humans; Hypok | 1971 |
The chemical composition of faeces in uraemia, as revealed by in-vivo faecal dialysis.
Topics: Ammonia; Anti-Bacterial Agents; Blood Urea Nitrogen; Dialysis; Feces; Humans; Hydrogen-Ion Concentra | 1968 |